Isolation of bioactive proteins from natural product extracts

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Barry  Okeefe
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2024
Award: $780,903
Funding agency: National Cancer Institute

As part of this project, the Protein Chemistry and Molecular Biology Section (PCMBS) has continued to discover new bioactive proteins including three new members of the reciting class of anti-cancer proteins and one new anti-SARS-CoV-2 and anti-his lectin, Dm-CVNH, a homolog of the protein cyanovirin-N. The protein cyanovirin-n itself was shown to have potent anti-SARS-CoV-2 activity and was shown tone active in animal studies. The protein Q-griffithsin, and oxidation resistant analog of the protein griffithsin, patented by the NCI, was found to be safe in Phase I clinical trials with a publication expected shortly. A new pre-fractionated marine aqueous extract was created by the Natural Products Branch based on methods developed in the PCMBS. This library, which will eventually number ~100,000 fractions, was found to be rich in potential biotherapeutics with numerous proteins and peptides showing biological activities. This library will be a key resource for the PCMBS moving forward.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D structure><3-dimensional structure><3D structure><Amino Acid Sequence><Animals><Antibodies><Biological><Biological Response Modifier Therapy><Biological Therapy><COVID-19 virus><COVID19 virus><Clinical><CoV-2><CoV2><Communities><Cyanovirin-N><DNA Molecular Biology><EXTMR><Early-Stage Clinical Trials><Evaluation><Extramural><Extramural Activities><Goals><Homologous Protein><Human><Lectin><Legal patent><Libraries><Ligands><Methods><Modern Man><Molecular Biology><Molecular Target><Natural Products><Natural Source><Nostoc ellipsosporum CV-N protein><Patents><Peptide/Protein Chemistry><Peptides><Phase 1 Clinical Trials><Phase I Clinical Trials><Primary Protein Structure><Protein Chemistry><Protein Homolog><ProteinHomolog><Proteins><Publications><R-Series Research Projects><R01 Mechanism><R01 Program><Reagent><Research><Research Grants><Research Project Grants><Research Projects><Research Resources><Resistance><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Source><Viral Cancer><Work><Wuhan coronavirus><analog><anti-cancer><anticancer activity><aqueous><biologic><biological therapeutic><biological treatment><biologically based therapeutics><biotherapeutics><biotherapy><clinical development><coronavirus disease 2019 virus><coronavirus disease-19 virus><hCoV19><marine><marine environment><member><nCoV2><naturally occurring product><novel><oxidation><peptide based natural products><peptide natural products><phase I protocol><protein sequence><resistant><three dimensional structure>